OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has made significant progress in the clinical development of its therapeutic candidate, urcosimod, which addresses inflammatory eye diseases and chronic pain. The data indicates that 67% of patients treated with 0.05% urcosimod experienced more than 50% improvement in pain, contrasting strongly with only 33% in the placebo group, highlighting the treatment's efficacy. Furthermore, the notable reduction in pain scores observed as early as Week 4 suggests a promising outlook for the company’s product pipeline and overall market potential in treating relevant conditions.

OKYO Pharma Ltd reported a net loss of $4.7 million, or $0.12 per share, for the fiscal year ending March 31, 2025, reflecting ongoing financial challenges. The clinical performance of the 0.05% urcosimod group is concerning, as all patients experienced moderate to severe pain, in stark contrast to the majority of placebo patients, suggesting potential efficacy issues. Additionally, various risks, including the possibility of clinical trial failures and regulatory setbacks, pose significant threats to the company's future commercial success and financial stability.